In vitro activity of ceftobiprole against Acinetobacter baumannii clinical isolates.
Acinetobacter baumannii is a multiresistant opportunistic nosocomial pathogen responsible for outbreaks worldwide. The main infection caused by this microorganism is nosocomial pneumonia, in particular ventilator-associated pneumonia in patients in Intensive Care Units. Treatment of these nosocomial infections is becoming problematic because the level of resistance to antimicrobial agents is rising. Ceftobiprole is a new cephalosporin with activity against Gram-positive and Gram-negative pathogens. This study evaluated the in vitro activity of ceftobiprole against a collection of 58 A. baumannii clinical isolates and showed that the activity of ceftobiprole was superior to ceftazidime and cefepime when the bla(ADC)-like gene was not expressed or was expressed at a low level.
Marti
Sara
S
Servei de Microbiologia, Centre de Diagnòstic Biomèdic, Hospital Clínic, Facultat de Medicina, Universitat de Barcelona, Barcelona, Spain.
Sánchez-Céspedes
Javier
J
Espinal
Paula
P
Vila
Jordi
J
D000151:Acinetobacter Infections / Q000382:microbiology*; D040981:Acinetobacter baumannii / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000077723:Cefepime; D002442:Ceftazidime / Q000494:pharmacology; D002511:Cephalosporins / Q000494:pharmacology*; D015870:Gene Expression; D005798:Genes, Bacterial; D006801:Humans; D007362:Intensive Care Units; D008826:Microbial Sensitivity Tests; D053717:Pneumonia, Ventilator-Associated / Q000382:microbiology*
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; C443755:ceftobiprole; D000077723:Cefepime; D002442:Ceftazidime